Navigation Links
Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
Date:5/16/2011

INDIANAPOLIS, May 16, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present data from more than 30 studies at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill., from June 3 – 7, 2011, including results from PARAMOUNT, a Phase III study of an ALIMTA-based continuation maintenance regimen for the treatment of advanced nonsquamous non-small cell lung cancer.  PARAMOUNT data will be included in the ASCO-sponsored press briefing the morning of June 5 followed by a presentation during the Lung Cancer Oral Abstract Session at ASCO later the same day.

At ASCO, Lilly will present the latest research results on ALIMTA® (pemetrexed for injection) and GEMZAR® (gemcitabine for injection), as well as ERBITUX® (cetuximab) with partners Bristol-Myers Squibb and Merck KGaA.

"Lilly Oncology is committed to exploring innovations that improve outcomes for all people living with cancer," said Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology.  "We believe that data from PARAMOUNT, and our other studies at ASCO, demonstrate Lilly's focus on tailored therapies, and commitment to addressing unmet needs in cancer care."

ALIMTA Oral Abstract Session:

  • Abstract # CRA7510: Sunday, June 5, 2011, 11:30 - 11:45 AM
    • PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC)
    • Author/Speaker: L. G. Paz-Ares, F. de Marinis, M. Dedui, M. Thomas, J.P. Pujol, P. Bidoli, O. Molinier, T.P. Sahoo, E. Laack, M. Reck, J. Corral, S. Melemed, W. John, N. Chouaki, A. Zimmermann, C. Visseren-Grul, C. Gridelli
    • Location: Hall D1

P-LLY

This press release contains forward-looking statements about the potential of ALIMTA and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly Oncology to Present New Data on Nine of Its Pipeline Molecules at ASCO 2011
2. Amylin Pharmaceuticals Files Suit Against Eli Lilly
3. Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trusts Grow What Works Campaign
4. U.S. District Court Order Maintains Patent Exclusivity for Lillys Cymbalta
5. Lilly and Medtronic Announce Drug-Device Collaboration for Parkinsons Disease
6. Lilly Declares Second-Quarter 2011 Dividend
7. Lilly Reports First-Quarter 2011 Results
8. Lilly Receives Complete Response Letter From FDA for Liprotamase for the Treatment of Exocrine Pancreatic Insufficiency
9. Avant Healthcare Marketing Receives 2010 Lilly Global Sustained Supplier Award
10. Lilly Confirms Date and Conference Call for First-Quarter 2011 Financial Results Announcement
11. Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... the "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" ... In-Mold Electronics, Smart Skin, Structural ... Structural electronics involves electronic and/or ... protective structures, replacing dumb structures such as vehicle ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology:
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... ... , ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter ... bar too high can result in disappointment, perhaps even self-loathing. However, those who set ... , Research from PsychTests.com reveals that behind the tendency to set low ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
Breaking Medicine News(10 mins):